



Nuvilex’s Subsidiary, Medical Marijuana Sciences, Inc., Appoints Dr. Mark L. Rabe as Chairman of its Scientific Advisory Board

SILVER SPRING, MD, December 6, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its wholly-owned subsidiary, Medical Marijuana Sciences, Inc. (MMS), has appointed Mark L. Rabe, M.D., as Chairman of its Scientific Advisory Board.

Dr. Mark Rabe, a leading figure in the emerging medical marijuana field, earned his medical degree at Northwestern University and is certified by the American Board of Integrative Holistic Medicine (ABIHM). He graduated summa cum laude from Benedictine University, earning his degree in biochemistry, and performed research in the area of cancer drug synthesis.

More recently, Dr. Rabe was Chief Medical Officer of California’s largest network of physician-owned medical cannabis evaluation centers. There he hired and trained medical personnel, organized public educational symposia and media outreach, conducted research and supervised the recommendation of medical cannabis to over 100,000 patients in 20 clinics across California.

He is Founder and Medical Director of Centric Wellness, a San Diego medical practice that offers natural health care services to attain optimal health and manage chronic medical conditions. He is also CEO of Green Medical Solutions, LLC, a company that offers educational programs and practice management consulting services to health care practitioners.

Nuvilex’s Chief Scientific Officer, Dr. Robert F. Ryan, commented, “We are pleased Dr. Rabe has accepted the appointment as the Chairman of the Scientific Advisory Board for Medical Marijuana Sciences, Inc. His knowledge and leadership on the MMS Scientific Advisory Board will be a valuable asset for advancing the use of marijuana constituents for medical treatments.”

About Nuvilex:

Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-Box™, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and diabetes are being built. The Company’s treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or “cancer-killing” form. Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-Box™ technology may play a role in these efforts.

Safe Harbor:

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding Nuvilex's financial position, business strategy, plans and objectives of management for future operations and business conditions are forward-looking statements.

Forward-looking statements involve inherent risks and uncertainties. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, the following: (i) general economic or business conditions; (ii) changes in legislation or regulatory requirements; (iii) conditions of the securities markets; (iv) Nuvilex's ability to raise capital; (v) changes in accounting principles, policies or guidelines; (vi) financial or political instability; and (vii) other economic, competitive, governmental, regulatory and technical factors affecting the plans, operations, products and services of Nuvilex.

Nuvilex has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the control of Nuvilex. Nuvilex does not assume any obligations to update any of these forward-looking statements.

More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.

Investor Relations Contact:

Marlin Molinaro

Marmel Communications, LLC

Ph: (702) 434-8692

mmolinarofc@aol.com